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Commentary
Bisphenol A (BPA) is a known environmental
estrogen that is used as the monomer to man-
ufacture polycarbonate plastic, the resin that
is used as linings for most food and beverage
cans, as dental sealants, and as an additive in
other widely used consumer products. BPA is
one of the highest-volume chemicals produced
worldwide; global BPA capacity in 2003 was
2,214,000 metric tons (> 6.4 billion lb), with
6–10% growth in demand expected per year
(Burridge 2003). Heat and contact with either
acidic or basic compounds accelerate hydroly-
sis of the ester bond linking BPA molecules in
polycarbonate and resins. Speciﬁcally, heating
of cans to sterilize food, the presence of acidic
or basic food or beverages in cans or poly-
carbonate plastic, and repeated washing of
polycarbonate products have all been shown
to result in an increase in the rate of leaching
of BPA (Brotons et al. 1995; Consumers
Union 1999; Howdeshell et al. 2003; Kang
and Kondo 2002; Kang et al. 2003; Olea et al.
1996; Raloff 1999). In addition, another
potential source of human exposure is water
used for drinking or bathing. Studies con-
ducted in Japan (Kawagoshi et al. 2003) and
in the United States (Coors et al. 2003) have
shown that BPA accounts for most estrogenic
activity that leaches from landﬁlls into the sur-
rounding ecosystem.
Convincing evidence that there is wide-
spread exposure to BPA is shown by the ﬁnd-
ing of Calafat et al. (2005) that 95% of urine
samples from people in the United States
examined by the Centers for Disease Control
and Prevention (CDC) have measurable BPA
levels [range, 0.4 ppb (10th percentile) to
8 ppb (95th percentile); median = 1.3 ppb].
As described by Calafat et al. (2005), these
levels are consistent with ﬁndings from other
countries. For example, levels of unconjugated
(parent) BPA in human blood and tissues are
also in the same 0.1–10 ppb range (Ikezuki
et al. 2002; Schonfelder et al. 2002) detected
by Calafat et al. (2005) in urine. Because
there is evidence that BPA is rapidly metabo-
lized (Volkel et al. 2002), these ﬁnding sug-
gest that human exposure to significant
amounts of BPA must be continuous and via
multiple sources. A relationship between
blood levels of BPA and body fat in women
has been reported (Takeuchi et al. 2004).
In this commentary, we document for
the scientific, public health, and regulatory
communities that exposure of experimental
animals to “low doses” of BPA, which result
in tissue levels within and even below the
range of human exposure, has been related to
adverse effects in a large number of recently
published studies. A recent case–control study
reporting that blood levels of BPA are related
to ovarian disease in women (Takeuchi et al.
2004) adds to our concern. A large number of
in vitro studies show that effects of BPA are
mediated by both genomic and nongenomic
estrogen-response mechanisms, with disrup-
tion of cell function occurring at doses as low
as 1 pM or 0.23 ppt (Wozniak et al. 2005).
Although the focus of most studies of effects
of BPA has been on its estrogenic activity,
recent reports indicating the potential to dis-
rupt thyroid hormone action (Moriyama et al.
2002; Zoeller et al. 2005) mean other modes
of action must also be considered. Very low
part-per-trillion doses of BPA also cause pro-
liferation of human prostate cancer cells via
binding to a mutant form of the androgen
receptor expressed in a subpopulation of
prostate cancer cells (Wetherill et al. 2002),
although BPA acts as an androgen antagonist
in the presence of the wild-type androgen
receptor (Lee et al. 2003; Paris et al. 2002)
and can also block testosterone synthesis
(Akingbemi et al. 2004). A comprehensive
document containing all of the low-dose BPA
references, as well as information concerning
mechanisms of action, pharmacokinetics,
sources of exposure, and exposure levels in
humans, is available online (Endocrine
Disruptors Group 2005).
Our current conclusion that widespread
exposure to BPA poses a threat to human
health directly contradicts several recent
reports from individuals or groups associated
with or funded by chemical corporations
[Association of Plastics Manufacturers in
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Bisphenol A (BPA) is the monomer used to manufacture polycarbonate plastic, the resin lining of
cans, and other products, with global capacity in excess of 6.4 billion lb/year. Because the ester
bonds in these BPA-based polymers are subject to hydrolysis, leaching of BPA has led to wide-
spread human exposure. A recent report prepared by the Harvard Center for Risk Analysis and
funded by the American Plastics Council concluded that evidence for low-dose effects of BPA is
weak on the basis of a review of only 19 studies; the report was issued after a delay of 2.5 years. A
current comprehensive review of the literature reveals that the opposite is true. As of December
2004, there were 115 published in vivo studies concerning low-dose effects of BPA, and 94 of
these report signiﬁcant effects. In 31 publications with vertebrate and invertebrate animals, signiﬁ-
cant effects occurred below the predicted “safe” or reference dose of 50 µg/kg/day BPA. An estro-
genic mode of action of BPA is conﬁrmed by in vitro experiments, which describe disruption of
cell function at 10– 12 M or 0.23 ppt. Nonetheless, chemical manufacturers continue to discount
these published findings because no industry-funded studies have reported significant effects of
low doses of BPA, although > 90% of government-funded studies have reported signiﬁcant effects.
Some industry-funded studies have ignored the results of positive controls, and many studies
reporting no signiﬁcant effects used a strain of rat that is inappropriate for the study of estrogenic
responses. We propose that a new risk assessment for BPA is needed based on a) the extensive new
literature reporting adverse effects in animals at doses below the current reference dose; b) the
high rate of leaching of BPA from food and beverage containers, leading to widespread human
exposure; c) reports that the median BPA level in human blood and tissues, including in human
fetal blood, is higher than the level that causes adverse effects in mice; and d) recent epidemiologic
evidence that BPA is related to disease in women. Key words: bisphenol A, dose response,
endocrine disruptors, low dose, nonmonotonic, risk assessment scientific integrity. Environ
Health Perspect 113:926–933 (2005). doi:10.1289/ehp.7713 available via http://dx.doi.org/
[Online 13 April 2005]Europe (APM) 2005; Gray et al. 2004;
Kamrin 2004; Purchase 2004]. For example, a
recently published report on BPA prepared by
a panel convened by the Harvard Center for
Risk Analysis (HCRA), which was funded by
the American Plastics Council (APC), con-
cluded that “the weight of the evidence for
low-dose effects is very weak” (Gray et al.
2004). However, the charge to the HCRA
panel, which was to perform a weight-of-the-
evidence evaluation of available data on the
developmental and reproductive effects of
exposure to BPA in laboratory animals, led to
an analysis of only 19 of 47 available published
studies on low-dose effects of BPA. The delib-
erations of the HCRA were in 2001–2002,
and accordingly, a cut-off date of April 2002
was selected for consideration of the published
literature. It is regrettable that the relevance of
the analysis was further undermined by a delay
of 2.5 years in publication of the report.
During the intervening time, between April
2002 and the end of 2004, a large number of
additional articles reporting low-dose effects of
BPA in experimental animals have been pub-
lished. The result is that by the end of 2004, a
PubMed (National Library of Medicine,
Bethesda, MD) search identified 115 pub-
lished studies concerning effects of low doses of
BPA in experimental animals.
The last U.S. Environmental Protection
Agency (EPA) risk assessment for BPA was
based on research conducted in the 1980s
[Integrated Risk Information System (IRIS)
1988]. The most recent risk assessment of
BPA was based on a comprehensive review of
the scientiﬁc literature conducted in 1998 by
the European Union, with some selected arti-
cles added through 2001, at which time few of
the 115 low-dose BPA studies had been pub-
lished [European Chemicals Bureau (ECB)
2003]. Below, we describe recent findings
concerning mechanisms mediating effects of
very low doses of BPA, the adverse effects
being reported in animals, and recent ﬁndings
from human studies. These published ﬁndings
lead us to strongly recommend that a new risk
assessment for BPA be initiated.
The Deﬁnition of “Low Dose”
The U.S. EPA considers “low-dose” effects of
environmental endocrine-disrupting chemi-
cals to refer to effects being reported for
chemicals at doses lower than those used in
traditional toxicologic studies conducted for
risk assessment purposes. For BPA, the lowest
dose studied for risk assessment purposes was
50 mg/kg/day, which is the currently accepted
lowest observed adverse effect level (LOAEL)
that was used to calculate a reference dose of
50 µg/kg/day based on experiments conducted
in the 1980s (IRIS 1988).
BPA is often described as a very “weak”
estrogen because in a few assay systems, such as
MCF-7 breast cancer cells in culture, the dose
of BPA required to stimulate cell proliferation
(~ 10–7 M or 23 ppb) is roughly 100,000 times
higher relative to estradiol, which stimulates
cell proliferation at approximately 10–12 M
(Welshons et al. 1999). This contrasts, how-
ever, with the stimulation by BPA of calcium
influx in MCF-7 cells that was significant at
the lowest dose tested, which was 10–10 M or
23 ppt (Walsh et al. 2005). BPA also stimu-
lated calcium inﬂux and prolactin secretion in
rat pituitary tumor cells at the lowest dose
tested (10–12 M or 0.23 ppt), and the magni-
tude of the response to BPA was similar to the
response to the same dose of estradiol
(Wozniak et al. 2005). It is difﬁcult to conceive
how a chemical that can alter cell function at
concentrations < 1 ppt can be characterized as
a “weak” endocrine disruptor.
Low-dose effects of endocrine-disrupting
chemicals such as BPA are mediated by
endocrine-signaling pathways that evolved to
act as powerful ampliﬁers, with the result that
large changes in cell function can occur in
response to extremely low concentrations
(Welshons et al. 2003). Thus, information
concerning the in vivo potency of estradiol is
critical with regard to predicting the in vivo
bioactivity of chemicals such as BPA. In vivo
potency of estrogenic chemicals is determined
by the afﬁnity of the chemical for the speciﬁc
type of estrogen receptor (ER) that mediates
the effect, the rate of absorption and metabo-
lism, and binding of the chemical to plasma
estrogen-binding proteins. The initial interest
in low-dose effects of BPA was based on the
observation that BPA showed limited binding
to plasma estrogen-binding proteins (Nagel
et al. 1997), which results in higher free plasma
BPA relative to estradiol. It is well known that
it is the free hormone level in blood that is pre-
dictive of biologic activity (Nagel et al. 1999).
A much higher free BPA concentration in
blood relative to estradiol would not be taken
into account in predicting its in vivo potency
based simply on cell culture studies conducted
in culture medium.
Before conducting the first low-dose
in vivo study with BPA, vom Saal et al. (1997)
found that an increase in size of the fetal
mouse prostate occurred in response to an
experimental increase in free serum estradiol in
fetuses of 0.1 pg/mL serum (0.1 ppt or
0.4 × 10–12 M), from 0.2 pg/mL in control
fetuses to 0.3 pg/mL free serum estradiol in
estrogen-exposed fetuses. Although this ﬁnding
was initially controversial, other in vivo and
in vitro studies have since conﬁrmed that very
low doses of the estrogenic drug diethylstilbe-
strol (DES) stimulate an increase in size of the
fetal mouse prostate (Gupta 2000; Timms
et al. 2005). Nagel et al. (1997) predicted the
dose of BPA (fed to pregnant mice) that
should be biologically active in mouse fetuses
based on a comparison of BPA and estradiol in
terms of both the relative afﬁnity for nuclear
ERs and binding to serum estrogen-binding
proteins that effectively restrict estradiol (but
not BPA) uptake into cells. This has been
referred to as a “physiologic approach” to dose
selection (vom Saal et al. 1998). Nagel et al.
(1997) chose the fetal prostate growth bioassay
to test the physiologically based prediction of
low-dose estrogenic activity of BPA, although
the prediction was that any estrogenic response
would be altered by exposure to BPA during
early development. Nagel et al. (1997) reported
ﬁnding an enlarged prostate in male offspring
after feeding pregnant mice 2 or 20 µg/kg/day
BPA. Because these doses are below the current
reference dose, this ﬁnding received a consider-
able amount of attention.
The ﬁndings by Nagel et al. (1997) raised a
critical question: Why were the estrogenic
effects that they observed below the current ref-
erence dose not predicted based on traditional
toxicologic studies that focused on the toxic
effects of very high doses of BPA (Morrissey
et al. 1987)? The toxicologic approach involves
dose selection based on the maximum tolerated
dose, which can be described as “top-down
dose selection,” whereas the physiologic
approach used by Nagel et al. (1997) can be
described as “bottom-up dose selection”
(Welshons et al. 2003). We show below that
there is now overwhelming evidence demon-
strating that these different experimental
approaches lead to very different conclusions of
safety with regard to the current reference dose
for BPA of 50 µg/kg/day. Findings based on
low-dose studies thus present a strong chal-
lenge to the assumptions that form the basis
for chemical risk assessments.
Why Did the APC Contract with
the HCRA to Write a Report on
Low-Dose Effects of BPA?
The controversy created by reports of ﬁndings
for BPA and other chemicals at “low doses,”
and studies funded by chemical corporations
that quickly disputed these ﬁndings, resulted in
the U.S. EPA asking the National Toxicology
Program (NTP) to host a meeting in October
2000 on the low-dose issue. The final NTP
Low Dose Peer Review report (NTP 2001)
was summarized by the co-chairs and session
organizers (Melnick et al. 2002). 
In contrast to today, at the time of the
NTP low-dose meeting there were relatively
few published low-dose studies with BPA.
However, the NTP report (NTP 2001) was
critical of some of the industry-funded studies
of BPA. For example, one industry-sponsored
study (Ashby et al. 1999) was criticized by the
NTP panel (NTP 2001, p. A9) for not iden-
tifying that the body weights and reproduc-
tive organ weights of the control animals were
significantly different from those of control
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to replicate (Nagel et al. 1997), and that the
study was not a true replication because of the
use of different animal feed. Another industry-
funded study that concluded that all ﬁndings
were not statistically signiﬁcant (Elswick et al.
2000) was harshly criticized by the NTP panel
as presenting conclusions that were “ﬂawed,”
“illogical,” and “misleading,” and the NTP
panel concluded that results were, in fact, sta-
tistically signiﬁcant (NTP 2001, p. A89).
When the initial report of the NTP
panel was released, the APC quickly issued a
public letter in which the conclusion of the
NTP panel—that there was “credible evi-
dence of low-dose effects”—was described as
“troubling . . . if not erroneous” (Bisphenol A
Global Industry Group 2000). The APC then
contracted with the HCRA in 2000, which
established a panel of scientists (including
coauthor C.H.) to perform a weight-of-the-
evidence evaluation of available data on the
developmental and reproductive effects of
exposure to BPA in laboratory animals. In
turn, the HCRA panel focused on 19 pub-
lished studies of the available 47 publications
and, particularly, on the effects of low doses
of BPA on development of the reproductive
system in male rodents. The conclusions in
the panel’s published report (Gray et al.
2004) were directed to this portion of the lit-
erature that was intensively scrutinized, but
the wording was promptly interpreted by
plastic industry trade organizations as suggest-
ing that a far more complete survey of the
BPA literature had been encompassed by the
panel’s review process (APM 2005; vom Saal
2005). As of April 2002, there were 47 avail-
able publications that could have been exam-
ined in a comprehensive review of all
low-dose effects of BPA in all species. Because
of the charge to the HCRA panel and its
response to that charge, it reviewed 7 of
9 (78%) of the industry-funded published
studies, but reviewed only 12 of 38 (38%) of
the government-funded studies that were
available in the published literature.
Current Status of Literature 
on Low-Dose Effects of BPA
Of a total of 115 published studies with low
doses of BPA below the prior LOAEL of
50 mg/kg/day that we accessed via a PubMed
search at the end of December 2004, there
have been 94 published studies reporting
in vivo estrogenic activity of BPA. Of the
94 low-dose studies reporting significant
effects, 31 published studies have reported
effects caused by doses of BPA at and below
the reference dose of 50 µg/kg/day.
Rate of growth and sexual maturation,
hormone levels in blood, reproductive organ
function, fertility, immune function, enzyme
activity, brain structure, brain chemistry, and
behavior are all affected by exposure to low
doses of BPA. Many of these effects are due
to exposure during early development (gesta-
tion and/or lactation), but effects due to
postweaning-through-adult exposure have
also been reported.
A comprehensive review of the rapidly
growing literature on adverse health effects of
low doses of BPA in vertebrates and inverte-
brates is beyond the scope of this commentary,
but references are available online (Endocrine
Disruptors Group 2005). We describe below
some examples of effects of low doses of BPA
in mice and rats.
• Increased postnatal growth in both males and
females occurred at maternal doses between
2.4 and 500 µg/kg/day (Honma et al. 2002;
Howdeshell et al. 1999; Nikaido et al. 2004;
Takai et al. 2000).
• Early onset of sexual maturation in females
occurred at maternal doses between 2.4 and
500 µg/kg/day (Honma et al. 2002;
Howdeshell et al. 1999; Nikaido et al. 2004).
• Altered plasma luteinizing hormone levels
occurred at a maternal dose of 2 µg/kg/day
(Akingbemi et al. 2004), and decreased
plasma testosterone in males occurred at a
maternal dose of 2 µg/kg/day (Akingbemi
et al. 2004; Kawai et al. 2003).
• An increase in prostate size in male offspring
occurred at maternal doses between 2 and
50 µg/kg/day (Gupta 2000; Nagel et al.
1997; Timms et al. 2005). A decrease in
daily sperm production and fertility in males
was also reported at doses between 0.2 and
20 µg/kg/day due to developmental or adult
exposure (Al-Hiyasat et al. 2002; Chitra
et al. 2003; Sakaue et al. 2001; vom Saal
et al. 1998).
• Stimulation of mammary gland develop-
ment in female offspring occurred at the
very low maternal dose of 0.025 µg/kg/day
delivered tonically by an Alzet pump
(Markey et al. 2001a). Significant disrup-
tion of the alignment of chromosomes dur-
ing meiosis was observed in developing
oocytes during puberty because of leaching
of BPA from polycarbonate drinking bottles
at doses between 15 and 70 µg/kg/day
(Hunt et al. 2003), and an increase in mor-
tality of embryos occurred at a maternal
dose of 25 µg/kg/day (Al-Hiyasat et al.
2004). Disruption of adult estrous cycles
occurred at maternal doses between 100 and
500 µg/kg/day (Nikaido et al. 2004;
Talsness et al. 2000).
• Altered immune function occurred at doses
between 2.5 and 30 µg/kg/day (Sawai et al.
2003; Yoshino et al. 2003, 2004).
• A decrease in antioxidant enzymes occurred
at the very low dose of 0.2 µg/kg/day in
adult males (Chitra et al. 2003).
• Changes in the brain include an increase in
progesterone receptor mRNA levels at
400 µg/kg/day (Funabashi et al. 2003), ER-α
levels at 40 µg/kg/day (Aloisi et al. 2001),
and ER-β mRNA levels at 25 µg/kg/day
(Ramos et al. 2003) and a change in brain
somatostatin receptors at 400 µg/kg/day
(Facciolo et al. 2002).
• Behavioral effects include hyperactivity at
30 µg/kg/day (Ishido et al. 2004), an
increase in aggressiveness at 2–40 µg/kg/day
(Farabollini et al. 2002; Kawai et al. 2003),
altered reactivity to painful or fear-provoking
stimuli at 40 µg/kg/day (Aloisi et al. 2002),
and impaired learning at 100 µg/kg/day
(Negishi et al. 2004). Developmental expo-
sure to BPA also resulted in a significant
change in the locus coeruleus, where BPA at
30 µg/kg/day reversed the normal sex differ-
ences in this brain structure and eliminated
sex differences in behavior (Kubo et al.
2003). Developmental exposure decreased
maternal behavior at 10 µg/kg/day (Palanza
et al. 2002), altered play and other socio-
sexual behaviors at 40 µg/kg/day (Aloisi et al.
2002; Dessi-Fulgheri et al. 2002), and
enhanced the behavioral response to drugs
such as amphetamine at 40–300 µg/kg/day
(Adriani et al. 2003; Suzuki et al. 2003).
Factors Accounting for the
Absence of Signiﬁcant Effects
in Low-Dose BPA Experiments
As of the end of 2004, we are aware of
21 studies that report no harm in response to
low doses of BPA. Source of funding is highly
correlated with positive or negative findings
in published articles. For government-funded
published studies, 94 of 104 (90%) report
significant effects at doses of BPA < 50
mg/kg/day. No industry-funded studies (0 of
11, or 0%) report significant effects at these
same doses (Table 1). It is thus reasonable to
pose two questions: a) Are government-funded
scientists under real or perceived pressure to
find or publish only data suggesting adverse
outcomes? b) Are industry-funded scientists
under real or perceived pressure to ﬁnd or pub-
lish only data suggesting negative outcomes?
It is important to determine what speciﬁc
factors, other than just source of funding, are
associated with reports of no signiﬁcant effects
of low doses of BPA. In this article we discuss
four issues, some of which have became appar-
ent because of ﬁndings published after the cut-
off date for the literature review in the HCRA
report: strain of experimental animal, misin-
terpretation of finding no significant effects
for the positive controls, animal feed, and spe-
ciﬁc end point examined.
Strain of experimental animal. The impor-
tance of the strain of animal used in low-dose
BPA research was acknowledged in the HCRA
report (Gray et al. 2004) as well as the previous
NTP report (NTP 2001). The NTP panel
emphasized the need to test for the sensitivity
vom Saal and Hughes
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control, such as the well-characterized estro-
genic drugs DES and ethinylestradiol, and
stated that
Because of clear species and strain differences in
sensitivity, animal model selection should be based
on responsiveness to endocrine active agents of
concern (i.e., responsive to positive controls), not
on convenience and familiarity. (NTP 2001,
p. vii)
A recent study has revealed the very low
sensitivity to any estrogen of the Charles-River
Sprague-Dawley (CD-SD) rat used in two
studies (Ema et al. 2001; Tyl et al. 2002) that
were heavily relied on by the HCRA panel in
drawing the conclusion “that the negative
ﬁndings for reproductive endpoints for rats are
more compelling than the positive findings”
(Gray et al. 2004). According to Charles River
Laboratories (2004), rats were purchased by
Charles River from Sprague-Dawley in 1950.
This colony was continuously subjected to
selective breeding for rapid postnatal growth
and large litter size, and then in both 1991
and 1997 new colonies were established from
selected animals.
Yamasaki et al. (2002) reported that the
CD-SD strain of rat showed some responses to
50-µg/kg/day ethinylestradiol administered for
28 days, and more responses to the very high
dose of 200 µg/kg/day. Ethinylestradiol is the
potent estrogenic drug used by women in birth
control pills at a dose of 0.5 µg/kg/day (based
on a body weight of 60 kg). The CD-SD rat
thus has a very low sensitivity to ethinylestra-
diol, because relative to women, it requires
100- to 400-fold higher doses to produce
effects. In contrast, the fetal male CF-1 mouse
examined in the initial vom Saal laboratory
studies with BPA responded to ethinylestradiol
with significant changes in adult sperm pro-
duction and prostate size at a maternal oral
dose of 0.002 µg/kg/day (Thayer et al. 2001).
The CF-1 male mouse fetus is thus between
25,000 and 100,000 times more sensitive to
ethinylestradiol relative to the CD-SD rat.
Yamasaki et al. (2002) also reported that
600 mg/kg/day BPA was required to see
effects in CD-SD rats. This dose is > 200,000
times higher than the BPA doses used in stud-
ies conducted in the vom Saal laboratory
(Howdeshell et al. 1999, Nagel et al. 1997),
and as indicated above, it is also dramatically
higher than doses of BPA required to cause
effects in > 90 other low-dose BPA studies
conducted with other types of rats, various
mouse strains, and other experimental verte-
brate and invertebrate animals. There are now
many studies that have been conducted with
rats other than the CD-SD strain that show
low-dose effects of BPA, but very few of these
studies were subject to review by the HCRA
panel (Gray et al. 2004).
All studies with CD-SD rats report the
absence of significant effects of low doses of
BPA (Table 1), although the conclusions in
one these studies (Elswick et al. 2000) were
questioned by the NTP panel (NTP 2001). If
the studies that used the CD-SD rat are elimi-
nated from consideration, 94 of 98 (96%)
government-funded studies report signiﬁcant
effects of low doses of BPA, whereas 0 of 8
(0%) industry-funded studies reports signiﬁ-
cant effects with the same low doses (Table 1).
Misinterpretation of the absence of signiﬁ-
cant ﬁndings for the positive controls. The very
low sensitivity of the CD-SD rat strain to BPA
was predicted by its low sensitivity to
ethinylestradiol when it was included as a posi-
tive control. Two industry-funded studies
(Ashby et al. 1999; Cagen et al. 1999) were
designed with DES included as a positive con-
trol, which was reported by industry spokes-
men (Toloken 1998) at a public news brieﬁng
about the Cagen et al. (1999) study. A critique
[Environmental Data Services (ENDS) 1998]
pointed out that the positive control, DES,
failed to show a difference from the negative
controls in each of these studies (Ashby et al.
1999; Cagen et al. 1999); however, the authors
did not indicate in their published articles that
DES had been used as the positive control.
Subsequent studies funded by chemical corpo-
rations, all of which have reported the absence
of significant effects for low doses of BPA,
avoided this problem by simply not including
a positive control in the experiment.
The NTP panel (NTP 2001) commented
on the issue regarding 
...a   study in which the positive control does not
produce the expected positive response. The pru-
dent course of action in such cases may be to
declare the study inadequate and repeat it, regard-
less of the experimental outcome in the test
groups. (NTP 2001, pp. 5–10)
The NTP panel went on to note that, 
For those studies that included DES exposure
groups, those that showed an effect with BPA
showed a similar low-dose effect with DES (e.g.,
prostate and uterus enlargement in mice), while
those that showed no effect with BPA also found
no effect with DES.
As articulated by the NTP panel (NTP 2001),
only by including a known estrogenic chemi-
cal, such as DES or ethinylestradiol, as a posi-
tive control in an experiment can the reason
for the failure to find low-dose estrogenic
effects of BPA be determined to be due to
either inactivity of the chemical, insensitivity
of the model animal, or some other variable,
such as the type of feed used.
Disruption of low-dose studies of
endocrine-disrupting chemicals by variability
in components of commercial animal feed. A
critical issue in experiments concerning effects
of low doses of estrogenic chemicals is that a
common rodent feed used in toxicologic stud-
ies has been reported by investigators at the
National Institute of Environmental Health
Sciences (Thigpen et al. 2003) to be highly
variable in its estrogenic activity. These inves-
tigators reported that some batches of this
feed were able to interfere with the ability to
detect puberty-accelerating effects of DES in
female CD-1 mice, due to the feed maximally
advancing the age at puberty in control females
(Thigpen et al. 2003). The use of this particu-
lar feed by Cagen et al. (1999) and Tyl et al.
(2002) raises the possibility that endocrine-
disrupting components in this feed played a
role in the failure of these studies to show
low-dose effects of BPA; Cagen et al. (1999)
also failed to find significant effects of the
positive control DES, whereas Tyl et al.
(2002) did not include a positive control. The
HCRA panel (Gray et al. 2004) relied heavily
on both of these studies.
Both the NTP (2001) and HCRA panels
(Gray et al. 2004) raised the possibility that
the type of feed used in some studies may
have affected the results, but the information
provided by Thigpen et al. (2003) about vari-
ability in estrogenic activity in different
batches of a feed commonly used in toxico-
logic studies, and other recent findings
regarding variability in endocrine-disrupting
components of feed other than phytoestrogens
(vom Saal et al. 2004, 2005), was not available
for either the NTP or the HCRA panel to
review. Thus, it is understandable that the
HCRA report could state: “Nor is there com-
pelling evidence that the type of feed adminis-
tered...can explain the negative results
reported” (Gray et al. 2004).
It is now clear that it is necessary to develop
a standard feed that is appropriate for studies
involving the examination of end points that
are sensitive to estrogenic chemicals, because
estrogenic as well as other components of feed
can be present in highly variable amounts in
different batches; levels of phytoestrogens in
plants vary in response to different environ-
mental conditions. The findings reported by
Thigpen et al. (2003) that effects of DES could
be masked by some batches of a commercial
feed clearly demonstrate that, without an
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Table 1. Biased outcome due to source of funding in low-dose in vivo BPA research as of December 2004.
All studies except
All studies CD-SD rat studies CD-SD rats
Source of funding Harm No harm Harm No harm Harm No harm
Government 94 (90.4) 10 (9.6) 0 (0%) 6 (100) 94 (96) 4 (4)
Chemical corporations 0 (0) 11 (100) 0 (0%) 3 (100) 0 (0) 8 (100)
Values shown are no. (%).appropriate positive control, false-negative ﬁnd-
ings can occur that lead to the false conclusion
that even biologically active doses of potent
estrogenic drugs such as DES have no effect.
The uterotrophic response is not stimulated
by low doses of BPA. Seven articles have
reported that low doses of BPA do not stimu-
late a uterotrophic response (Ashby and
Odum 2004; Diel et al. 2004; Gould et al.
1998; Laws et al. 2000; Markey et al. 2001b;
Mehmood et al. 2000; Tinwell et al. 2000).
For example, a dose of 100 mg/kg/day BPA
injected subcutaneously was required to stim-
ulate an increase in uterine weight in pre-
pubertal CD-1 mice (Markey et al. 2001b).
This is in marked contrast to the fetal CD-1
mouse prostate (Gupta 2000; Timms et al.
2005), testes (Kawai et al. 2003), mammary
glands (Markey et al. 2001a), and brain
(Palanza et al. 2002), which all respond to
doses of BPA at and far below the reference
dose of 50 µg/kg/day. In order to assess the
effects of low doses of BPA or other estro-
genic endocrine-disrupting chemicals on the
uterus, more sophisticated approaches are
required than just measuring uterine weight
(Markey et al. 2001b; Newbold et al. 2004).
Implications for Risk
Assessments of Low-Dose 
BPA Effects
As noted above, BPA is a widely used chemi-
cal, with a capacity in excess of 6.4 billion lb
in 2003. If regulatory agencies were to deter-
mine that the actual LOAEL for BPA is below
the current reference dose of 50 µg/kg/day, the
15 corporations that manufacture BPA would
be affected economically (Burridge 2003).
However, corporations that manufacture prod-
ucts made from BPA would be less affected
because alternatives to BPA already exist for
many products. Potential economic impacts
need to be considered in relation to the impli-
cations for human health of the wide range of
adverse effects caused by exposure to very low
doses of BPA in the animal experiments
described above.
Measurements of current human contami-
nation indicate that exposure of human fetuses
to BPA already occurs at levels within the
range demonstrated to cause adverse effects in
fetal rodents (Schonfelder et al. 2002).
Speciﬁcally, Zalko et al. (2002) injected preg-
nant CD-1 mice subcutaneously on gestation
day 17 with 25 µg/kg tritiated BPA; parent
(unconjugated) BPA levels in mouse fetuses at
0.5, 2, and 24 hr after administration were
4.20, 0.48, and 0.13 ng/g (ppb), respectively.
Schonfelder et al. (2002) reported that parent
BPA levels in human fetal serum ranged from
0.2 to 9.2 ng/mL (ppb), and the median was
2.3 ng/mL (ppb). Many adverse effects have
been reported in offspring due to maternal
doses of ≤ 25 µg/kg/day in mice.
That the adverse effects being observed at
low doses of BPA in animal experiments
should be of concern with regard to human
health is shown by a study comparing BPA
levels in nonobese and obese women in Japan
who had normal ovarian function or poly-
cystic ovarian disease. In this case–control
study Takeuchi et al. (2004) reported signiﬁ-
cantly higher blood levels of BPA both in
obese women and in women with polycystic
ovarian disease. These findings suggest that
the adverse effects due to exposure to low
doses of BPA in experimental animals may be
predictive of adverse effects in adult humans.
The implications of these results extend
beyond BPA, because they may lead to require-
ments that hazard assessments be designed to
detect analogous low-dose impacts of other
chemicals. Acknowledgment of the existence of
the large number of studies showing unique
low-dose effects of BPA could lead to the
demand that, in designing studies to assess the
hazards of all chemicals for risk assessment pur-
poses, a wider range of doses must be exam-
ined, as opposed to only a few very high doses
based on the maximum tolerated dose. This
would require accepting that extrapolation
from data on effects at very high doses (based
on the linear-threshold model) is not valid for
endocrine-disrupting chemicals (vom Saal and
Sheehan 1998; Welshons et al. 2003).
We posed above the question concerning
why a large number of estrogenic effects have
been observed in studies that examined low
doses of BPA, but these effects were not pre-
dicted based on traditional toxicologic studies
that focused on the toxic effects of very high
doses of BPA. When evidence of a non-
monotonic, inverted-U dose–response relation-
ship is found in a toxicologic study, the results
are often identified as not showing a dose–
response relationship. Although findings in
toxicologic studies that occur within a low-
dose range but not at higher doses are typically
discounted or, at best, considered to be rare,
just for BPA there are currently 11 in vivo and
in vitro examples of unique effects seen at low
doses but not at higher doses (e.g., Endocrine
Disruptors Group 2005; Oehlmann et al.
2000; Wetherill et al. 2002; Welshons et al.
2003; Wozniak et al. 2005).
The inverted-U dose–response phenome-
non shows that dose selection is critical in
studies of chemicals such as BPA, and older
toxicologic studies that just examined a few
very high doses are not relevant for assessing
the possibility of unique effects that only
occur within a specific low-dose range. The
mechanisms mediating qualitative changes in
response over a wide range of doses are now
being elucidated at multiple levels, such as
gene-response profile (Coser et al. 2003),
changes in tissue expression of receptors
(Gupta 2000), and changes in neuroendocrine
feedback systems (Rubin et al. 2001; Talsness
et al. 2000). Low doses of a hormone can
stimulate a response, whereas much-higher
doses inhibit the same response, and this phe-
nomenon is so well established that it is used
in clinical endocrinology to treat diseases
(Kappy et al. 1989; Welshons et al. 2003).
Although endocrinologists find it plausible
that there are unique effects caused by low
doses of a chemical with hormonal activity
that might not be observed at much higher
doses, this has not been recognized by regula-
tory agencies involved in risk assessments.
It is important to keep in mind that tradi-
tional toxicologic testing of chemicals for regu-
latory purposes requires examination of only a
few very high doses of a chemical, which often
do not exceed 50-fold below the maximum
tolerated dose (vom Saal and Sheehan 1998).
The maximum tolerated dose of BPA is very
high (~ 1,250,000 µg/kg/day; Morrissey et al.
1987; IRIS 1988). In contrast, a wide range of
adverse effects in 31 published studies have
been reported in offspring due to administer-
ing pregnant mice and rats doses of BPA
25,000 times lower than the maximum toler-
ated dose (Endocrine Disruptors Group 2005).
The conclusion from these published ﬁndings
is that examining only a 50-fold dose range on
the basis of the maximum tolerated dose is a
seriously ﬂawed approach for assessing adverse
effects of chemicals that are mediated by highly
sensitive endocrine-response mechanisms.
Regulatory agencies readily accept that the
predicted reference dose is actually “safe” with-
out ever requiring that this dose be veriﬁed in
an experiment to cause no adverse effects
(vom Saal and Sheehan 1998; Welshons et al.
2003). Regulatory agencies need to acknowl-
edge that there is now overwhelming evidence
for adverse effects of one of the highest-volume
chemicals in commerce below the previously
predicted “safe” daily dose for humans. This
should lead to the requirement that new risk
assessments be conducted to reevaluate the
safety of other chemicals, in addition to BPA.
Conclusions and
Recommendations
In summary, a comprehensive up-to-date
analysis by regulatory agencies is needed to
evaluate the potential hazards to humans from
exposure to BPA at doses below the prior
LOAEL of 50 mg/kg/day; low doses of BPA
have now been reported to alter brain chem-
istry and structure, behavior, the immune sys-
tem, enzyme activity, the male reproductive
system, and the female reproductive system in
a variety of animals, including snails, fish,
frogs, and mammals. There are also a number
of in vitro studies showing that the particular
type of ER (α or β) and the speciﬁc coregula-
tors present in cells can markedly inﬂuence the
dose of BPA required to stimulate a response
vom Saal and Hughes
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with estrogen-responsive tissues within the
same animal showing marked differences in
the dose of BPA required to elicit a response.
Not all effects of BPA are mediated by the
classical nuclear ERs (α and β). Very low part-
per-trillion doses of BPA can stimulate
responses in cultured mouse pancreas cells, rat
pituitary tumor cells, and human breast cancer
cells via rapid induction of calcium uptake
(Quesada et al. 2002; Walsh et al. 2005;
Wozniak et al. 2005); these same low doses of
BPA stimulate proliferation in mouse (Gupta
2000) and human (Wetherill et al. 2002)
prostate cells in culture. Nongenomic cell sig-
naling systems involve serial activation of
kinases via ligand binding to receptors associ-
ated with the cell membrane, and these path-
ways are known to have tremendous amplifying
capacity.
In the now outdated perspective of the
HCRA report (Gray et al. 2004), it was stated
that “In the case of BPA the only proposed
mechanism for low-dose effects is through
modulation of the [nuclear] estrogen recep-
tor.” Instead, the recent findings concerning
the multiple mechanisms of action of BPA
show that at concentrations < 1 ppt, BPA
activates receptors associated with the plasma
membrane of selected target cells. As the BPA
“dose at target” increases, various responses in
the same or different cells are activated or
inhibited (MacLusky et al. 2005), with the
speciﬁc dose required being dependent on the
subtype of nuclear ER and specific coactiva-
tors or coinhibitors that are present. At even
higher concentrations (parts per billion to
parts per million), inhibition of androgen-
stimulated and thyroid-hormone–stimulated
responses can also occur. That the integrated
output across a 1-million-fold dose range can
be nonmonotonic (inverted-U shape) is thus
not unexpected by scientists who study hor-
mones and hormonally active drugs or chemi-
cals (Welshons et al. 2003). Regulatory
agencies that conduct risk assessments have not
addressed the implications of nonmonotonic
dose–response curves for endocrine-disrupting
chemicals with regard to the linear-threshold
model currently used to predict “safe” doses
for humans.
The in vitro findings at low (and even
sub) part-per-trillion doses of BPA have to be
viewed in relation to potential effects of free
(unconjugated and unbound) BPA levels in
human blood. Data from numerous studies
show that unconjugated BPA in human
blood and tissues is in the low part-per-billion
range (Endocrine Disruptors Group 2005)
and that BPA shows limited binding to
human plasma binding proteins that regulate
the uptake of estrogenic chemicals into tissues
(Nagel et al. 1999). Importantly, new analyti-
cal methods have been developed since the
published literature was reviewed in 1998 for
the last BPA risk assessment conducted by the
European Union (ECB 2003). These new
methods have now made it possible to detect
BPA in blood within the range that it shows
biologic activity, which was not previously the
case. There is thus convincing evidence that
biologically active levels of BPA in human
blood are above the range that has been
demonstrated to cause changes in function in
human tissues based on in vitro studies.
The literature we reviewed shows that the
rate of leaching from commonly used BPA-
containing products (the lining of tin cans and
polycarbonate food and beverage containers) is
high enough to result in adverse effects in labo-
ratory animals (Raloff 1999). These recently
published ﬁndings indicate that the accepted
migration limit [recently set by the European
Union (ECB 2003)] of 30 ppb BPA from
polycarbonate or resins into food and bever-
ages is not sufficiently protective of human
health. The case–control study reporting that
ovarian disease in Japanese women is related to
blood levels of BPA provides a ﬁrst conﬁrma-
tion of this prediction in adult humans
(Takeuchi et al. 2004).
Almost one-half of the low-dose BPA
studies have been published in just the last
2 years, and there were only five published
low-dose BPA studies as of 1998 when the
initial comprehensive literature search was
conducted for the last risk assessment con-
ducted by the European Union (ECB 2003).
A thorough analysis of the entire published
low-dose BPA literature associated with a new
risk assessment by regulatory agencies that
takes into account the issues discussed here
and elsewhere is now warranted (vom Saal
2005; vom Saal and Sheehan 1998; vom Saal
et al. 2004, 2005, in press; Welshons et al.
2003). It is important that a reexamination of
the BPA low-dose literature include a discus-
sion of the requirement for appropriate posi-
tive controls, which was identified by the
NTP panel as a signiﬁcant problem in studies
claiming to ﬁnd no low-dose effects.
The initial NTP review concerning BPA
as a carcinogen concluded that “there was no
convincing evidence that [BPA] was carcino-
genic,” because the background level of can-
cer was high in untreated males (NTP 1982).
This conclusion has been criticized by a scien-
tist in the NTP: Huff (2002) concluded that,
if these findings (NTP 1982) were officially
reanalyzed based on the approach to inter-
preting cancer in animal studies used today,
BPA would be interpreted as being associated
with an increase in tumors of blood cells, the
testes, and the mammary glands.
In summary, a new risk assessment is
needed to establish a new LOAEL and a new
reference dose for BPA based on the extensive
new information from low-dose studies. In
addition, the low-dose literature for BPA and
other endocrine-disrupting chemicals shows
that regulatory agencies need to begin the
process of reevaluating the assumptions that
provide the basis for the linear-threshold
model used in risk assessments.
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